overview   |   leadership   |   founders   |   scientific advisory board   |   investors

scientific advisory board

Agios has assembled a world class Scientific Advisory Board featuring some of the most renowned scientific experts within the fields of cancer metabolism, oncology, drug discovery, and translational medicine. These advisors work closely with Agios scientists in a variety of ways to identify new research directions and to accelerate Agios' target validation and drug discovery programs.

Chair of the Scientific Advisory Board:
Craig B. Thompson, M.D., University of Pennsylvania and Abramson Cancer Center

Paul S. Anderson, Ph.D., Retired executive of Bristol-Myers Squibb and Merck

James E. Bradner, M.D., Dana-Farber Cancer Institute and Harvard Medical School

Lewis C. Cantley, Ph.D., Beth Israel Deaconess Medical Center and Harvard Medical School

Chi Dang, M.D., Ph.D., The Johns Hopkins Family Professor in Oncology Research; Professor of Medicine, Cell Biology, Oncology and Pathology; Vice Dean for Research, School of Medicine

Ronald A. DePinho, M.D., Dana-Farber Cancer Institute and Harvard Medical School

William G. Kaelin Jr., M.D., Dana-Farber Cancer Institute and Harvard Medical School

Tak W. Mak, Ph.D., University of Toronto and The Campbell Family Institute for Breast Cancer Research

Pier Paolo Pandolfi, M.D., Ph.D., Beth Israel Deaconess Medical Center

Homer L. Pearce, Ph.D., Retired executive of Eli Lilly & Company

David M. Sabatini, M.D., Ph.D., Whitehead Institute and Massachusetts Institute of Technology

Charles Sawyers, M.D., Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center

Bruce M. Spiegelman, Ph.D., Dana-Farber Cancer Institute and Harvard Medical School

[ back to top ]